HANXBIO Executes HKD 1.06 Million Share Buyback, Lifts Treasury Stock to 0.25% of Mandated Limit

Bulletin Express

Apr 24

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO; H-share) disclosed a share repurchase on 24 April 2026, reducing its outstanding share count and increasing treasury stock as follows:

• Transaction details: 36,300 H-shares were bought back on the Hong Kong Stock Exchange at prices ranging from HKD 28.00 to HKD 31.36, for a total consideration of HKD 1.06 million. The volume-weighted average cost stands at HKD 29.14 per share.

• Capital structure impact: Issued shares (excluding treasury shares) fell 0.03% from 135.91 million to 135.88 million. Treasury shares rose from 304,200 to 340,500, keeping total issued shares unchanged at 136.22 million.

• Utilisation of repurchase mandate: The company is authorised to buy back up to 13.62 million shares. Cumulative purchases under this mandate now total 340,500 shares, equal to 0.25% of the authorised amount.

• Governance and compliance: The board-sanctioned repurchase complied with Hong Kong Listing Rules and domestic regulations. A 30-day moratorium on new share issues or treasury-share sales applies until 24 May 2026.

The disclosure was signed by Chairman and Executive Director Mr Zhang Faming on 24 April 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1182854264"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182854264\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182854264?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182854264","market":"hk","top_or_hot":-1,"title":"HANXBIO Executes HKD 1.06 Million Share Buyback, Lifts Treasury Stock to 0.25% of Mandated Limit","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO; H-share) disclosed a share repurchase on 24 April 2026, reducing its outstanding share count and increasing treasury stock as follows:</p>\n<p>• Transaction details: 36,300 H-shares were bought back on the Hong Kong Stock Exchange at prices ranging from HKD 28.00 to HKD 31.36, for a total consideration of HKD 1.06 million. The volume-weighted average cost stands at HKD 29.14 per share.</p>\n<p>• Capital structure impact: Issued shares (excluding treasury shares) fell 0.03% from 135.91 million to 135.88 million. Treasury shares rose from 304,200 to 340,500, keeping total issued shares unchanged at 136.22 million.</p>\n<p>• Utilisation of repurchase mandate: The company is authorised to buy back up to 13.62 million shares. Cumulative purchases under this mandate now total 340,500 shares, equal to 0.25% of the authorised amount.</p>\n<p>• Governance and compliance: The board-sanctioned repurchase complied with Hong Kong Listing Rules and domestic regulations. A 30-day moratorium on new share issues or treasury-share sales applies until 24 May 2026.</p>\n<p>The disclosure was signed by Chairman and Executive Director Mr Zhang Faming on 24 April 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO Executes HKD 1.06 Million Share Buyback, Lifts Treasury Stock to 0.25% of Mandated Limit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO Executes HKD 1.06 Million Share Buyback, Lifts Treasury Stock to 0.25% of Mandated Limit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-24 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO; H-share) disclosed a share repurchase on 24 April 2026, reducing its outstanding share count and increasing treasury stock as follows:</p>\n<p>• Transaction details: 36,300 H-shares were bought back on the Hong Kong Stock Exchange at prices ranging from HKD 28.00 to HKD 31.36, for a total consideration of HKD 1.06 million. The volume-weighted average cost stands at HKD 29.14 per share.</p>\n<p>• Capital structure impact: Issued shares (excluding treasury shares) fell 0.03% from 135.91 million to 135.88 million. Treasury shares rose from 304,200 to 340,500, keeping total issued shares unchanged at 136.22 million.</p>\n<p>• Utilisation of repurchase mandate: The company is authorised to buy back up to 13.62 million shares. Cumulative purchases under this mandate now total 340,500 shares, equal to 0.25% of the authorised amount.</p>\n<p>• Governance and compliance: The board-sanctioned repurchase complied with Hong Kong Listing Rules and domestic regulations. A 30-day moratorium on new share issues or treasury-share sales applies until 24 May 2026.</p>\n<p>The disclosure was signed by Chairman and Executive Director Mr Zhang Faming on 24 April 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1182854264","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182854264","pubTimestamp":1777035807,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO; H-share) disclosed a share repurchase on 24 April 2026, reducing its outstanding share count and increasing treasury stock as follows: •...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"HANXBIO执行106万港元股票回购，将库存股提高至法定限额的0.25%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO; H-share) disclosed a share repurchase on 24 April 2026, reducing its outstanding share count and increasing treasury stock as follows:\n• Transaction details: 36,300 H-shares were bought back on the Hong Kong Stock Exchange at prices ranging from HKD 28.00 to HKD 31.36, for a total consideration of HKD 1.06 million. The volume-weighted average cost stands at HKD 29.14 per share.\n• Capital structure impact: Issued shares (excluding treasury shares) fell 0.03% from 135.91 million to 135.88 million. Treasury shares rose from 304,200 to 340,500, keeping total issued shares unchanged at 136.22 million.\n• Utilisation of repurchase mandate: The company is authorised to buy back up to 13.62 million shares. Cumulative purchases under this mandate now total 340,500 shares, equal to 0.25% of the authorised amount.\n• Governance and compliance: The board-sanctioned repurchase complied with Hong Kong Listing Rules and domestic regulations. A 30-day moratorium on new share issues or treasury-share sales applies until 24 May 2026.\nThe disclosure was signed by Chairman and Executive Director Mr Zhang Faming on 24 April 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}